A randomized phase III trial demonstrated that patients with GC expressing PD-L1 had a worse prognosis after pembrolizumab combined chemotherapy, which includes cisplatin, fluorouracil and capecitabine (82). The gene discussed is CD274; the disease is gastric cancer.